Next Phase Newsletter

A venture capital firm in the USA had its beginnings as an incubator, providing seed funding to very early-stage companies for the first two years. Since then, the firm has also branched into a venture arm that expanded the investment focus to Series A financing rounds. The firm is actively seeking investments and will allocate around $500K – 2.5 M, with preferred financing structures being equity and convertible preferred equity. Although the firm has invested in companies outside the USA, the firm focuses its investments on USA-based companies.

In the life sciences space, the firm is primarily interested in healthcare IT/digital health technologies and services as well as medical devices and diagnostic tools that have a tech-enabled component. The firm is open to devices of all FDA regulatory pathways including 510k and PMA. Products that have not begun clinical trials will most likely be considered too early, so these devices should at least be undergoing clinical trials. The firm is not interested in companies in the therapeutics sector.

The firm seeks to work with privately owned companies with an experienced management team that is dedicated full-time. CEOs with experience founding successful start-up companies is a strong plus. The firm can act as either a lead or co-investor in financing rounds, and will generally seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm is a $300 million strategic corporate venture capital fund by a Japanese pharma. The fund seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The firm will also consider the option-type of investments and spin-outs, in addition to pure equity investments. The fund is currently seeking opportunities in the USA, Europe and Japan, the focus being mainly in USA and Europe.

The firm will consider early-stage (generally research to pre-IND) first-in-class/new biology-based approaches in drug discovery and innovative platform technologies for drug discovery, especially assets that have a strategic angle to TPC’s pipeline. The firm considers a wide variety of modalities (biologics/oncolytic viruses and small molecules) as well as cell and gene therapy on an opportunistic basis. The firm’s primary indication of interest is oncology, but the firm is also interested in immunology, allergy, musculoskeletal, and orphan indications. While the firm is primarily focused on therapeutics, the firm may review technologies in medical device, diagnostic, or digital health sectors if there is a strong strategic alignment.

The firm is looking for teams with strong sector expertise. With the support of the parent company’s established expertise in the field of oncology product discovery and development, The firm will provide financial resources and company outreach to build strategic alliances to help translate novel research and high potential drug candidates into cornerstone products. The firm may request regional option or rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a hybrid family office and operating company based on the East Coast. The firm can make investments ranging from approximately $500,000 to $100 million into companies and due to its funding structure has no requirements for holding period or capital structure. The firm makes investments in the forms of equity, controlling interest, in-licensing, MBO/LBO, growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes around 5-15 investments in a given year.

The firm is looking for companies in sectors of Biotech Therapeutics and Diagnostics, Medtech, Digital Health, R&D Services, and Biotech Other. The firm is willing to consider all indications including orphan diseases, though they have some additional interest/experience is areas of Women’s Health, GI, Oncology and Cardiovascular, and Personalized Medicine including Proteomics and Genomics. The firm is most interested in companies that are in Phase II or later, nearing commercialization where the firm is capable of utilizing its operating company to scale up the company’s sales, marketing and distribution. That being said the firm has made earlier stage investments in the past and is open to considering highly innovative and compelling early stage companies. The firm is also interested in companies developing consumables/reagents, service providers, food and nutraceuticals.

The firm looks to work with management teams with experience and grit and generally looks to take a board seat although it is not a requirement. The firm looks to leverage the use of its operating company to assist the company’s sales marketing and distribution efforts as well as providing assistance in operations management.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a healthcare-focused venture capital firm that was founded in 1982. Its offices are located in the Midwest. The firm has over $200 million in assets under management and is currently investing out of its sixth fund. The firm makes seed and early-stage investments in healthcare companies, with typical initial investment sizes ranging from $250k to $3.5 million, and total investment up to $8 million over the life cycle of a company. Venture Investors is a regional fund and focused on investments in the Midwest.

The firm focuses on early-stage investments in biopharma, medtech, tools/dx and digital health sectors. The firm is interested in platform technologies that can improve patient outcomes while lowering the cost of care.

The firm looks for experienced management teams with previous start-up experience, industry knowledge, and proven track records as well as scientific founders who are committed to building world class management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Founded in 1986 with offices in the US and Ireland, a venture capital firm recently closed its latest fund, the firm’s largest fund to date with over $1.85B. The firm’s size of investment can largely vary; the firm can invest as little as $50K all the way up to hundreds of millions over the life of investment. The firm is open to investment opportunities globally.

The firm is currently interested in novel concepts and platforms across the life sciences. The firm invests in therapeutics, devices, diagnostics, life science tools, and has a lesser interest in technology-led companies in the healthcare IT space (the firm is not interested in service-based/SaaS healthcare IT businesses). The firm has made many investments in these particular areas: infectious disease, mental health, immunology, genomic and biological tools, data sciences and ways of reimagining diagnostics and therapies. The firm prefers early stage opportunities; in therapeutics, the firm focuses on pre-IND technologies.

The firm only invests in privately held companies that have not previously raised a Series A round or a significant seed round. The firm is a highly hands-on, active investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

Established in 1941, a pharmaceutical company is headquartered in Tokyo, Japan, operating globally in terms of R&D, manufacturing, distribution and marketing, with a strong focus on prescription medicines. The corporate investment arm of the company has offices in USA and a headquarter in Tokyo, Japan. The firm has a budget of $140M USD ($15B JPY) to make strategic equity investments in early-stage companies that align with the company’s core business. The firm will invest between $1-5M in seed to mid-stage companies, with Series A being the sweet spot. The firm is open to global opportunities.

The firm is interested in opportunities that are synergistic with their research and development pipeline in neurology and oncology. The firm is interested in pharmaceutical drugs across various modalities, including but not limited to antibodies, peptides, nucleic acids, and cell/gene therapy. The firm is also interested in digital therapeutics, IT solutions, and diagnostics. Within neurology, the firm is strongly interested in (but not limited to) neurodegenerative diseases including Alzheimer’s Disease and Parkinson’s Disease as well as epilepsy and sleep disorders. Within oncology, the firm is interested in solid tumors (breast, liver, lung, etc).

The firm is a flexible investor and can act as a lead or follow-on investor. The corporate venture investment closely collaborates with the firm’s business development and leverages its global network of pharmaceuticals, research universities, etc. to identify and collaborate with cutting-edge opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A medical device company based in California, USA, with offices worldwide is interested in partnering with medical technology companies. Depending on the stage of the company, these partnerships may include follow-on investments in early-stage equity investments, joint technology development, commercial agreements or acquisitions. The firm typically does not act as a lead investor in equity rounds. The firm can partner with companies based anywhere in the world.

The firm is interested in technologies that strategically align with the firm’s core business. Areas of interest include new technology in 2D and 3D imaging, visualization, 3D printing, materials science, and digital health and AI, and diagnostics for oral diseases. The firm generally partners with companies at an early stage of development.

The firm can partner with companies at any stage but the type of partnership depends on the maturity of the company; for example, the firm may form joint development agreements with early stage companies or make equity investments, and for later stage companies may form commercial or distribution agreements.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.